IRINOTECAN INTAS irinotecan hydrochloride trihydrate 300 mg/15 mL concentrated injection vial

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

irinotecan hydrochloride trihydrate, Quantity: 300 mg

Disponible depuis:

Accord Healthcare Pty Ltd

forme pharmaceutique:

Injection, concentrated

Composition:

Excipient Ingredients: hydrochloric acid; sodium hydroxide; lactic acid; water for injections; sorbitol

Mode d'administration:

Intravenous Infusion

Unités en paquet:

1

Type d'ordonnance:

(S4) Prescription Only Medicine

indications thérapeutiques:

Irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. Irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Descriptif du produit:

Visual Identification: A pale yellow clear solution; Container Type: Vial; Container Material: Glass Type I Coloured; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

Statut de autorisation:

Registered

Date de l'autorisation:

2020-03-05